Cargando…

Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy

Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jianan, Hu, Yiyang, Peng, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103580/
https://www.ncbi.nlm.nih.gov/pubmed/33962586
http://dx.doi.org/10.1186/s11658-021-00254-z
_version_ 1783689334437707776
author Zhao, Jianan
Hu, Yiyang
Peng, Jinghua
author_facet Zhao, Jianan
Hu, Yiyang
Peng, Jinghua
author_sort Zhao, Jianan
collection PubMed
description Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis. Here, we summarize the state of knowledge on the signaling mechanisms for each type and, based on their characteristics, discuss how they might be relevant in MAFLD-related pathological mechanisms. Although significant challenges exist in the translation of fundamental science into clinical therapy, this review should provide a theoretical basis for innovative MAFLD clinical treatment plans that target programmed cell death.
format Online
Article
Text
id pubmed-8103580
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81035802021-05-10 Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy Zhao, Jianan Hu, Yiyang Peng, Jinghua Cell Mol Biol Lett Review Most currently recommended therapies for metabolic dysfunction-associated fatty liver disease (MAFLD) involve diet control and exercise therapy. We searched PubMed and compiled the most recent research into possible forms of programmed cell death in MAFLD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis. Here, we summarize the state of knowledge on the signaling mechanisms for each type and, based on their characteristics, discuss how they might be relevant in MAFLD-related pathological mechanisms. Although significant challenges exist in the translation of fundamental science into clinical therapy, this review should provide a theoretical basis for innovative MAFLD clinical treatment plans that target programmed cell death. BioMed Central 2021-05-07 /pmc/articles/PMC8103580/ /pubmed/33962586 http://dx.doi.org/10.1186/s11658-021-00254-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Zhao, Jianan
Hu, Yiyang
Peng, Jinghua
Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title_full Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title_fullStr Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title_full_unstemmed Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title_short Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
title_sort targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (mafld): a promising new therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103580/
https://www.ncbi.nlm.nih.gov/pubmed/33962586
http://dx.doi.org/10.1186/s11658-021-00254-z
work_keys_str_mv AT zhaojianan targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy
AT huyiyang targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy
AT pengjinghua targetingprogrammedcelldeathinmetabolicdysfunctionassociatedfattyliverdiseasemafldapromisingnewtherapy